Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Conditions

• Recurrent Plasmablastic Lymphoma
• Refractory Plasmablastic Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo buccal swab and blood sample collection
• Computed Tomography — PROCEDURE
  Undergo PET/CT
• Positron Emission Tomography — PROCEDURE
  Undergo PET/CT
• Teclistamab — DRUG
  Given SC

Study Details

This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving teclistamab may be safe and tolerable in treating patients with recurrent or refractory plasmablastic lymphoma.

Key Dates

First listed

Jan 12, 2026

Start date

Mar 26, 2027

Status verified

Jun 2026

Primary completion

Dec 31, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

30 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (teclistamab)
  Patients receive teclistamab SC on days 1, 4, and 7 in the absence of disease progression or unacceptable toxicity (i.e., Cycle 1). Beginning 1 week later, patients receive teclistamab SC on day 1 (i.e., Cycle 2). Beginning 1 week later, 2 weeks later, or 4 weeks later (based on dose level), patients receive teclistamab SC on day 1 of remaining cycles. Based on dose level, cycles repeat weekly, every 2 weeks, or every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who have achieved a CR by cycle 13 may discontinue study treatment. Patients achieving less than a CR but benefiting from treatment may continue to receive teclistamab beyond 13 cycles in the absence of disease progression, unacceptable toxicity, or achieving a CR. Additionally, patients undergo optional buccal swab collection at baseline and optional blood sample collection throughout the study. Patients also undergo PET/CT throughout the study.

Primary Outcome Measure

Incidence of adverse events [ Time Frame: Up to 28 days after last dose of study treatment ]

Locations (1)

Find similar trials in Duarte, CA

Related Studies

• Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
  Recruiting · AIDS Malignancy Consortium · La Jolla, California